دورية أكاديمية
أعرض في EDS

Biallelic TET2 mutations confer sensitivity to 5'-azacitidine in acute myeloid leukemia.

التفاصيل البيبلوغرافية
العنوان: Biallelic TET2 mutations confer sensitivity to 5'-azacitidine in acute myeloid leukemia.
المؤلفون: Stölzel F; Medical Clinic and Polyclinic I, University Hospital Dresden, Technical University of Dresden, Dresden, Germany., Fordham SE; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom., Nandana D; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom., Lin WY; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom., Blair H; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom., Elstob C; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom., Bell HL; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom., Mohr B; Medical Clinic and Polyclinic I, University Hospital Dresden, Technical University of Dresden, Dresden, Germany., Ruhnke L; Medical Clinic and Polyclinic I, University Hospital Dresden, Technical University of Dresden, Dresden, Germany., Kunadt D; Medical Clinic and Polyclinic I, University Hospital Dresden, Technical University of Dresden, Dresden, Germany., Dill C; Medical Clinic and Polyclinic I, University Hospital Dresden, Technical University of Dresden, Dresden, Germany., Allsop D; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom., Piddock R; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom., Soura EN; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom., Park C; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom., Fadly M; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom., Rahman T; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom., Alharbi A; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom., Wobus M; Medical Clinic and Polyclinic I, University Hospital Dresden, Technical University of Dresden, Dresden, Germany., Altmann H; Medical Clinic and Polyclinic I, University Hospital Dresden, Technical University of Dresden, Dresden, Germany., Röllig C; Medical Clinic and Polyclinic I, University Hospital Dresden, Technical University of Dresden, Dresden, Germany., Wagenführ L; Medical Clinic and Polyclinic I, University Hospital Dresden, Technical University of Dresden, Dresden, Germany., Jones GL; Department of Hematology, Freeman Hospital, Newcastle upon Tyne, United Kingdom., Menne T; Department of Hematology, Freeman Hospital, Newcastle upon Tyne, United Kingdom., Jackson GH; Department of Hematology, Freeman Hospital, Newcastle upon Tyne, United Kingdom., Marr HJ; Department of Hematology, Freeman Hospital, Newcastle upon Tyne, United Kingdom., Fitzgibbon J; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Onel K; Icahn School of Medicine at Mount Sinai, New York, New York, USA., Meggendorfer M; MLL Munich Leukemia Laboratory, Munich, Germany., Robinson A; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom., Bziuk Z; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom., Bowes E; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom., Heidenreich O; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom., Haferlach T; MLL Munich Leukemia Laboratory, Munich, Germany., Villar S; Department of Hematology, Clínica Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain., Ariceta B; Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Navarra, Spain.; IdiSNA, Navarra, Spain., Diaz RA; Hematology Department, Hospital 12 de Octubre (i+12), Centro Nacional de Investigaciones Oncológicas (CNIO), Complutense University, Madrid, Spain., Altschuler SJ; Department of Pharmaceutical Chemistry, School of Pharmacy, University of California, San Francisco, San Francisco, California, USA., Wu LF; Department of Pharmaceutical Chemistry, School of Pharmacy, University of California, San Francisco, San Francisco, California, USA., Prosper F; Department of Hematology, Clínica Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain., Montesinos P; Hospital Universitario y Politécnico La Fe, Valencia, Spain., Martinez-Lopez J; Hematology Department, Hospital 12 de Octubre (i+12), Centro Nacional de Investigaciones Oncológicas (CNIO), Complutense University, Madrid, Spain., Bornhäuser M; Medical Clinic and Polyclinic I, University Hospital Dresden, Technical University of Dresden, Dresden, Germany.; National Center for Tumor Diseases, Dresden, Germany., Allan JM; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
المصدر: JCI insight [JCI Insight] 2023 Jan 24; Vol. 8 (2). Date of Electronic Publication: 2023 Jan 24.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: Electronic Cited Medium: Internet ISSN: 2379-3708 (Electronic) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Ann Arbor, Michigan : American Society for Clinical Investigation, [2016]-
مواضيع طبية MeSH: Leukemia, Myeloid, Acute*/genetics , Dioxygenases*/genetics, Humans ; Mice ; Animals ; Azacitidine ; Kaplan-Meier Estimate ; Mutation ; DNA-Binding Proteins/genetics
مستخلص: Precision medicine can significantly improve outcomes for patients with cancer, but implementation requires comprehensive characterization of tumor cells to identify therapeutically exploitable vulnerabilities. Here, we describe somatic biallelic TET2 mutations in an elderly patient with acute myeloid leukemia (AML) that was chemoresistant to anthracycline and cytarabine but acutely sensitive to 5'-azacitidine (5'-Aza) hypomethylating monotherapy, resulting in long-term morphological remission. Given the role of TET2 as a regulator of genomic methylation, we hypothesized that mutant TET2 allele dosage affects response to 5'-Aza. Using an isogenic cell model system and an orthotopic mouse xenograft, we demonstrate that biallelic TET2 mutations confer sensitivity to 5'-Aza compared with cells with monoallelic mutations. Our data argue in favor of using hypomethylating agents for chemoresistant disease or as first-line therapy in patients with biallelic TET2-mutated AML and demonstrate the importance of considering mutant allele dosage in the implementation of precision medicine for patients with cancer.
References: J Clin Oncol. 2018 Jun 20;36(18):1788-1797. (PMID: 29702001)
Oncotarget. 2017 Jun 27;8(26):43295-43305. (PMID: 28476038)
Oncotarget. 2014 Jun 30;5(12):4384-91. (PMID: 24962689)
Nucleic Acids Res. 2015 Apr 20;43(7):e47. (PMID: 25605792)
Blood. 2011 Oct 27;118(17):4509-18. (PMID: 21803851)
Leukemia. 2018 Dec;32(12):2546-2557. (PMID: 30275526)
J Clin Oncol. 2012 Apr 20;30(12):1350-7. (PMID: 22430270)
F1000Res. 2016 Jun 08;5:1281. (PMID: 27347385)
Blood. 1995 Mar 1;85(5):1202-6. (PMID: 7858250)
N Engl J Med. 2009 May 28;360(22):2289-301. (PMID: 19474426)
Cancer Cell. 2018 Jan 8;33(1):44-59.e8. (PMID: 29275866)
N Engl J Med. 2017 Aug 3;377(5):454-464. (PMID: 28644114)
BMC Cancer. 2019 Apr 25;19(1):389. (PMID: 31023266)
Cancer Discov. 2019 Jul;9(7):872-889. (PMID: 31076479)
Blood. 2011 Nov 17;118(20):5593-603. (PMID: 21881046)
Blood. 2009 Jul 2;114(1):144-7. (PMID: 19420352)
Bioinformatics. 2014 May 15;30(10):1363-9. (PMID: 24478339)
Cancer Epidemiol. 2016 Jun;42:186-98. (PMID: 27090942)
Leuk Lymphoma. 2014 Dec;55(12):2691-8. (PMID: 24524305)
Leukemia. 2017 Dec;31(12):2815-2823. (PMID: 28555081)
Oncotarget. 2017 Oct 27;8(63):106948-106961. (PMID: 29291002)
Genes Chromosomes Cancer. 2014 Oct;53(10):824-32. (PMID: 24898826)
Cancer. 2021 Jun 15;127(12):2003-2014. (PMID: 33626197)
Leukemia. 2011 Dec;25(12):1840-8. (PMID: 21681191)
Leukemia. 2011 Jul;25(7):1147-52. (PMID: 21494260)
J Clin Oncol. 2011 Apr 1;29(10):1373-81. (PMID: 21343549)
Blood. 2014 Oct 23;124(17):2705-12. (PMID: 25224413)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
Leukemia. 2020 Dec;34(12):3161-3172. (PMID: 32231256)
Cell Cycle. 2012 Nov 1;11(21):4079-92. (PMID: 23095522)
Science. 2004 Apr 2;304(5667):104-7. (PMID: 15064419)
Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2548-53. (PMID: 24550281)
N Engl J Med. 2012 Mar 22;366(12):1079-89. (PMID: 22417203)
N Engl J Med. 2022 Apr 21;386(16):1519-1531. (PMID: 35443108)
Haematologica. 2015 Sep;100(9):e351-3. (PMID: 26045292)
Cancer Cell. 2015 Apr 13;27(4):502-15. (PMID: 25873173)
Oncogene. 2013 Sep 12;32(37):4331-42. (PMID: 23085751)
Nat Genet. 2011 May;43(5):491-8. (PMID: 21478889)
Cancer Cell. 2010 Dec 14;18(6):553-67. (PMID: 21130701)
Cell Syst. 2020 Jul 22;11(1):86-94.e5. (PMID: 32619551)
Hematol Oncol. 2017 Dec;35(4):864-868. (PMID: 27353473)
N Engl J Med. 2016 Jun 9;374(23):2209-2221. (PMID: 27276561)
Br J Haematol. 2015 Mar;168(6):913-6. (PMID: 25312805)
Nucleic Acids Res. 2019 May 7;47(8):e47. (PMID: 30783653)
Cancer Cell. 2011 Jul 12;20(1):11-24. (PMID: 21723200)
JAMA. 2015 Aug 25;314(8):811-22. (PMID: 26305651)
Leukemia. 2018 Aug;32(8):1751-1761. (PMID: 29795413)
Leukemia. 2012 May;26(5):934-42. (PMID: 22116554)
Bioinformatics. 2013 Jan 1;29(1):15-21. (PMID: 23104886)
Blood Adv. 2019 Feb 12;3(3):339-349. (PMID: 30709865)
Cancer Discov. 2017 May;7(5):494-505. (PMID: 28193779)
Blood. 2017 Jan 26;129(4):424-447. (PMID: 27895058)
Blood. 2010 Aug 19;116(7):1132-5. (PMID: 20489055)
Blood. 2010 Jun 24;115(25):5222-31. (PMID: 20368469)
Leukemia. 2018 Jul;32(7):1598-1608. (PMID: 29472724)
Haematologica. 2013 Apr;98(4):591-6. (PMID: 23242596)
Nat Commun. 2018 Mar 21;9(1):1163. (PMID: 29563491)
Clin Cancer Res. 2022 Jul 1;28(13):2753-2761. (PMID: 35046058)
Blood. 1990 Nov 1;76(9):1704-9. (PMID: 2224119)
Nat Genet. 2009 Jul;41(7):838-42. (PMID: 19483684)
Toxicol In Vitro. 2015 Oct;29(7):1405-15. (PMID: 26009263)
Nat Med. 2011 Mar;17(3):291-3. (PMID: 21383741)
معلومات مُعتمدة: 13044 United Kingdom CRUK_ Cancer Research UK; 13044 United Kingdom LLR_ Blood Cancer UK
فهرسة مساهمة: Keywords: Cancer; Hematology; Leukemias; Molecular genetics
المشرفين على المادة: M801H13NRU (Azacitidine)
EC 1.13.11.- (TET2 protein, human)
0 (DNA-Binding Proteins)
EC 1.13.11.- (Dioxygenases)
EC 1.13.11.- (Tet2 protein, mouse)
تواريخ الأحداث: Date Created: 20221208 Date Completed: 20230125 Latest Revision: 20240306
رمز التحديث: 20240306
مُعرف محوري في PubMed: PMC9977313
DOI: 10.1172/jci.insight.150368
PMID: 36480300
قاعدة البيانات: MEDLINE
الوصف
تدمد:2379-3708
DOI:10.1172/jci.insight.150368